Industry news

• The Evolution of Marketing to Parents: Improving Representation

  06 December 2021 FiercePharma

  Before we can granulate family representation, we first need to understand how we differentiate families. Traditionally-represented families have parents in a heterosexual partnership raising child(ren) together in the same household; non-traditionally-represented families have a single parent raising child(ren), in an extended family household, in a chosen family household, or a LGBTQ+ parent. 

• IQVIA releases tool to connect nurses, phlebotomists with clinical trial patients in their homes

  06 December 2021 Kyle LaHucik / FirceBiotech

  Decentralized clinical trials have steamrolled into the mainstream of the drug development world. To improve the virtual process, IQVIA is connecting clinical trial patients in their homes with nurses and phlebotomists. 

• 'What it takes': Beyond the headlines, women are pushing groundbreaking new Alzheimer's treatments forward

  03 December 2021 Annalee Armstrong / FierceBiotech

  This past year has seen a flurry of attention on Alzheimer’s disease, and the medical community is closer than ever to having treatments that could reverse the devastating neurological disorder.

• Russian President Vladimir Putin instructed the government to prepare an action plan within a week to deal with the strain called omicron

  03 December 2021 GxPnews

  The Russian government has to prepare an updated action plan in a week to counter omicron strain of coronavirus infection. This was announced on Tuesday, November 30, during the plenary session of the VTB Capital investment forum “Russia Calling!” by Russian President Vladimir Putin.

• RDIF states when Sputnik V against the omicron strain will be available on the market

  02 December 2021 GxPnews

  Manufacturers of Sputnik V and Sputnik Lite vaccines against coronavirus will be able, if necessary, to supply hundreds of millions of doses of the vaccine adapted against the omicron strain to the markets by February 20, 2022, said Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF).

• Targeting senescent cells may fight insulin resistance

  01 December 2021 John Fox / BioWorld

  Investigators have identified a previously unrecognized population of senescent cells, called p21high cells, in fat tissue and demonstrated their contributory role in metabolic dysfunction, obesity, insulin resistance and type 2 diabetes.

• Five Key Strategies for Enhancing Diversity in Clinical Trials

  01 December 2021 PhRMA

  A new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Deloitte Center for Health Solutions (CHS) outlines five critical strategies for enhancing diversity in clinical trials during the research and development of new medicines. The report, titled “Enhancing Clinical Trial Diversity: Stakeholder Perspectives on Advancing Research Through Representative Clinical Trials,” is based on a year-long stakeholder engagement effort that included research and feedback from more than 500 stakeholders across 150+ organizations, including community stakeholders, experts in clinical trials and in racial justice, patient advocates, health care practitioners, pharmaceutical companies, academia, and more.

• Optimize Scale-Up for Vaccine and Therapeutic Manufacturing

  30 November 2021 FierchBiotech

  To meet the urgent demand for SARS-CoV-2 vaccines and therapeutics in the shortest possible timeframe, many companies are designing their scale-up processes in parallel with Phase III clinical trials, redefining the risk tolerance for everyone involved. To satisfy commercial requirements for expedited scale-up, the molecule can no longer dictate the technology transfer process into the manufacturing facility.

• RDIF states when Sputnik V against the omicron strain will be available on the market

  30 November 2021 GxPnews

  Manufacturers of Sputnik V and Sputnik Lite vaccines against coronavirus will be able, if necessary, to supply hundreds of millions of doses of the vaccine adapted against the omicron strain to the markets by February 20, 2022, said Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF).

• Social media is transforming our understanding of drug safety

  29 November 2021 Daniel Ghinn / European Pharmaceutical Review

  Social media has transformed people’s lives. From Twitter to Tumblr, it is estimated that by 2025 more than half the world’s population (4.41 billion people) will use social media in some form. As engagement rises so too does the level of information shared. Advancements in our capacity to monitor and interpret this information is also improving.